Shire halts development of drug for depression

Unsatisfactory late-stage clinical trials performance to blame for decision

Shire’s Vyvanse failed to ease symptoms of attention deficit hyperactivity disorder

Shire’s Vyvanse failed to ease symptoms of attention deficit hyperactivity disorder

 

Pharmaceuticals group Shire has halted development of its top-selling hyperactivity drug Vyvanse as a treatment for depression after it failed to treat patients successfully in two late-stage clinical trials. The news sent the drugmaker’s high-flying shares down by about 2 per cent to £30.80, but they rebounded to finish at £31.22.

Amphetamine-based Vyvanse, prescribed to US students to control attention deficit hyperactivity disorder, did not ease symptoms significantly when given as an add-on therapy for adults who had responded inadequately to two common types of antidepressants, Shire said late on Thursday.

London-listed Shire said it would no longer pursue the clinical development programme. Chief executive Flemming Ornskov said the news was “disappointing”. – (Reuters)